These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28399693)

  • 1. Pembrolizumab in recurrent advanced cervical squamous carcinoma.
    Martínez P; Del Campo JM
    Immunotherapy; 2017 May; 9(6):467-470. PubMed ID: 28399693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Minion LE; Tewari KS
    Gynecol Oncol; 2018 Mar; 148(3):609-621. PubMed ID: 29666026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab for the treatment of cervical cancer.
    Marret G; Borcoman E; Le Tourneau C
    Expert Opin Biol Ther; 2019 Sep; 19(9):871-877. PubMed ID: 31322926
    [No Abstract]   [Full Text] [Related]  

  • 4. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy.
    Day F; Kumar M; Fenton L; Gedye C
    J Immunother; 2017 Jan; 40(1):36-38. PubMed ID: 27684455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab in Recurrent Squamous Cell Carcinoma of the Vulva: Case Report and Review of the Literature.
    Shields LBE; Gordinier ME
    Gynecol Obstet Invest; 2019; 84(1):94-98. PubMed ID: 30016784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity of Pembrolizumab in Recurrent Cervical Cancer: Case Series and Review of Published Data.
    Kranawetter M; Röhrich S; Müllauer L; Obermair H; Reinthaller A; Grimm C; Sturdza A; Köstler WJ; Polterauer S
    Int J Gynecol Cancer; 2018 Jul; 28(6):1196-1202. PubMed ID: 29787422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update.
    Verhoeven Y; Quatannens D; Trinh XB; Wouters A; Smits ELJ; Lardon F; De Waele J; van Dam PA
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Lung Cancer.
    Du L; Herbst RS; Morgensztern D
    Hematol Oncol Clin North Am; 2017 Feb; 31(1):131-141. PubMed ID: 27912829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pembrolizumab for advanced cervical cancer: safety and efficacy.
    De Felice F; Giudice E; Bolomini G; Distefano MG; Scambia G; Fagotti A; Marchetti C
    Expert Rev Anticancer Ther; 2021 Feb; 21(2):221-228. PubMed ID: 33183120
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
    Dyer BA; Zamarin D; Eskandar RN; Mayadev JM
    J Natl Compr Canc Netw; 2019 Jan; 17(1):91-97. PubMed ID: 30659133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
    Dang TO; Ogunniyi A; Barbee MS; Drilon A
    Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma.
    Fischer S; Hasan Ali O; Jochum W; Kluckert T; Flatz L; Siano M
    Oncol Res Treat; 2018; 41(6):391-394. PubMed ID: 29734143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rapid response to pembrolizumab in a patient with metastatic melanoma.
    Bayo Calero J; Aviñó Tarazona V
    Immunotherapy; 2017 Mar; 9(3):225-228. PubMed ID: 28231724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma.
    Longoria TC; Tewari KS
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1247-53. PubMed ID: 27485741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports.
    Tung HJ; Wang CC; Liu FY; Lai CH
    Taiwan J Obstet Gynecol; 2021 Sep; 60(5):938-941. PubMed ID: 34507680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix.
    Zong L; Zhang Q; Zhou Y; Kong Y; Yu S; Chen J; Zhang Y; Xiang Y
    J Immunol Res; 2020; 2020():1283632. PubMed ID: 32322590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches.
    Remon J; Pardo N; Martinez-Martí A; Cedrés S; Navarro A; Martinez de Castro AM; Felip E
    Lung Cancer; 2017 Apr; 106():70-75. PubMed ID: 28285697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II trial of tricyclic nucleoside phosphate in patients with advanced squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study.
    Feun LG; Blessing JA; Barrett RJ; Hanjani P
    Am J Clin Oncol; 1993 Dec; 16(6):506-8. PubMed ID: 8256767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Medical treatment of metastatic or recurrent cancer of the cervix].
    de la Motte Rouge T; Pautier P; Hamy AS; Duvillard P; Bruna A; Castaigne D; Morice P; Haie-Meder C; Lhommé C
    Bull Cancer; 2006 Mar; 93(3):263-70. PubMed ID: 16567313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.